NCT00688714View on ClinicalTrials.gov

Study to Investigate Safety and Tolerability of a Single Dose of AZD6482

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Antiplatelet Effect
Interventions
DRUG

AZD6482

0,9-364,5 mg administrated through intravenous infusion over 3 hours

DRUG

Placebo

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY